Hemorrhagic Stroke
Conditions
Keywords
Astragulus polysaccharides, Hemorrhagic stroke
Brief summary
Astragalus membranaceus (AM) is used to treat stroke for a long time, and a number of studies have shown that AM can reduce cerebral infarction area and has anti-oxidation activity. PG2, a sterile powder of polysaccharides isolated from the root of astragulus (Huang-Chi) for intravenous injection, has been approved as a botanical drug by TFDA. Hemorrhagic stroke will induce secondary peri-blood clot edema and that may increase intracranial pressure to exacerbate clinical symptom. Therefore, the purpose of the present study was to investigate the efficacy of PG2 on hemorrhagic stroke.
Detailed description
This will be a double-blind, randomized, placebo-controlled study. An estimated 60 (at least 48 evaluable) first hemorrhagic stroke patients will be randomly divided into the control and treatment groups. Each group will be treated as follows: 1) control group will accept placebo t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.; 2) treatment group will accept PG2 t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. Inflammatory index including the levels of C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels will be measured and clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), Functional Independence Measure (FIM) and Barthel Index (BI) will be evaluated during this study.
Interventions
DRUGPG2
Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
DRUGPlacebo
500 ml normal saline, tiw, 2 weeks
Sponsors
PhytoHealth Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who confirmed diagnosis of first spontaneous hemorrhagic stroke * Patients with hemorrhagic stroke in Putamen * Patients who admitted to the hospital within 24 hours of onset of hemorrhagic stroke * Patients who signed the informed consent form
Exclusion criteria
* Patient with hemorrhage in the area out of Putamen or primary subarachnoid hemorrhage, Arteriovenous malformation (AVM) or brain tumor hemorrhage * Patient who performed craniotomy * Patient who suffering from cirrhosis, uremia with dialysis, bleeding tendency, severe cardiopulmonary disease or mental disorders would be unable to comply with the study by investigators' decision. * Patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening. * Female patients are pregnant or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional Independence Measure (FIM) | FIM will be evaluated on day 1 (baseline, before study drug treatment), day 7, day 28 and day 84. |
Secondary
| Measure | Time frame |
|---|---|
| Other clinical symptoms including Glasgow outcome scale (GOS), modified rankin scale (MRS), and Barthel Index (BI) | These clinical symptoms will be evaluated on on day 1 (baseline, before study drug treatment), day 7, day 28 and day 84. |
| Inflammatory index including C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), S-100 protein, IL-1, IL-6, and TNF-beta levels. | These index will be detected on day 1 (baseline, before study drug treatment), day 4 and day 7. |
Countries
Taiwan
Outcome results
None listed